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Objectives: To demonstrate the health economic impact of OM-85, a bacterial 
lysates based immunostimulant, for its approved indications in China. MethOds: 
A cost effectiveness decision tree model was constructed. The model compared 
OM-85 with the best supportive care therapy for the treatment of chronic bronchi-
tis and rhinosinusitis in Chinese population. Clinical efficacy and adverse events 
(AE) data were included in the model based on a thorough literature review. All 
localized direct treatment costs, including drug cost, AE costs, and medical treat-
ment costs for underlining diseases were included from Chinese payer perspective 
for both OM-85 and best supportive care group. A Key Opinion Leaders (KOL) survey 
was conducted to validate the local treatment costs. A total of 20 senior physi-
cians specialized in respiratory, ENT, allergy, and immunology fields were selected 
from tertiary hospitals in Beijing, Shanghai, Guangzhou, Hangzhou, Chongqiong, 
Chengdu and Wuhan to form an representative geographic sample. All physicians 
were requested to complete a questionnaire which included the clinical manage-
ment of acute exacerbation of chronic bronchitis and rhinosinusitis in China, the 
management of OM-85 related AEs, and the attitude towards the clinical efficacy 
and effects of OM-85. Incremental cost effectiveness ratio (ICER) was calculated 
based on the above efficacy and cost information. Results: The results indicate 
that, when compared with best supportive care therapy,OM-85 is a dominant 
therapy (with better clinical efficacy and lower overall costs) in Chinese popula-
tion for the clinical management of chronic bronchitis and rhinosinusitis One 
way sensitivity analyses were performed and the ICER result was demonstrated 
to be robust. cOnclusiOns: Based on its clinical efficacy in preventing acute 
exacerbations of chronic bronchitis and rhinosinusitis, OM-85, when compared 
with standard care therapy, proved to be a dominant therapy (better clinical effi-
cacy and lower overall costs) in Chinese population for the clinical management 
of chronic bronchitis and rhinosinusitis.
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Objectives: Unmotivated smokers are a unique population and have rarely 
been specifically targeted for recruitment into smoking cessation trials. While 
accurate cost data are essential to estimate resource utilization in replicating 
an intervention, currently the costs of recruiting unmotivated smokers are not 
reported in the literature. We aim to describe the costs and recruitment meth-
ods associated with successful enrollment of smokers who are unmotivated to 
quit. MethOds: Economic analysis was conducted on data from KC-Quest trial, 
an NIH funded large RCT comparing the efficacy of Motivational Interviewing 
(MI), matched intensity health education (HE), and brief advice (BA) for prompting 
quit attempts and cessation among smokers low in motivation to quit smoking. 
In this study retrospective analysis of cost data was performed to identify direct 
and activity-based time costs incurred for recruitment purposes. Costs were ana-
lyzed from the perspective of a researcher that seeks to replicate this recruitment 
protocol. To determine the most cost effective option to recruit patients for the 
trial one-way sensitivity analysis using a tornado diagram was conducted. All 
costs are reported in 2012 dollar values. Results: A total of 774 persons were 
screened for participation, and 255 were ultimately enrolled in the study. Overall 
cost of recruitment totaled $16,931.94 (direct costs= $12,252.50; activity-based 
time costs= $4,679.43), translating to $21.88 per recruitment contact and $66.40 
per successfully enrolled participant. The most successful recruitment methods 
were newspaper advertisements and word-of-mouth. Financial incentives also 
motivated many to participate. cOnclusiOns: We are the first to report the cost 
of recruiting smokers with low motivation to quit and shed light on this unique 
challenge. Study results may inform decision-makers, researchers, and clinicians 
seeking to enroll for unmotivated smokers. This economic analysis can serve as a 
guide to determine the budget for actively enrolling these patients in future trials 
and suggests the most efficient means to do so.
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Objectives: The purpose of this study is to assess health status of Korean adults 
with COPD using EQ5D and the association between health status and disease 
severity using spirometry as a lung function measure. MethOds: A stratified 
multistage clustered probability design was used to select a nationally repre-
sentative sample. From the Fourth and Fifth Korea National Health and Nutrition 
Examination Survey, 20,261 adults over the age of 40 years were selected. These 
subjects completed the utility measure, EQ-5D-3L and were separated into four 
severity groups according to FEV1 percent of predicted normal using the GOLD 
clinical guideline. Population sampling weights were applied to adjust for the 
over-sampling of the minority groups. Regression analysis was conducted using 
EQ-5D as the dependent variable to estimate the association between COPD and 
EQ-5D index score with SAS Ver. 9.3 program. Results: Among 20,261 adults, 
2,087 COPD patients were selected based on GOLD criteria (a ratio of FEV1 to 
FVC of less than 0.7). The mean utility of COPD patients was 0.906(SE 0.004) com-
pared to 0.922(SE 0.001) in the non-COPD control group. Utility was significantly 
reduced due to COPD(p= 0.0001). Within each GOLD stage, the variation (SE) was 
Objectives: Bacterial lysates reduce acute exacerbations for patients with 
chronic obstructive pulmonary disease. The purpose of this study was to conduct 
a cost-benefit analysis of bacterial lysates from a payer perspective through the 
results from a Meta analysis and a Delphi panel survey in China. MethOds: A 
cost-benefit analysis was to project the 12-month health benefits and costs asso-
ciated with immunostimulation treatments. Acute exacerbations were served as 
a measure of effectiveness. Treatment effectiveness data were derived from the 
meta-analysis. Costs were obtained from a Delphi panel survey of treating acute 
exacerbation for chronic obstructive pulmonary disease in China. One-way sensi-
tivity analysis was used to explore each parameter’s impacts on the uncertainty 
of the results. Results: The group receiving routine care only was dominated by 
the group with bacterial lysates plus routine care. Sensitivity analysis proved the 
robustness of the results. For a COPD patient, compared to the routine care as 
control group, the alternative treatment with bacterial lysates could reduce 1.9 
exacerbations in 12 months (WMD, -1.865; 95% CI, -2.128 to -1.603; P< 0.00001). The 
projected 12-month cost savings of a patient receiving bacterial lysates plus routine 
care was CNY14476. The cost of patients receiving bacterial lysates plus routine care 
was significantly lower than those receiving routione care only. cOnclusiOns: 
For patients with COPD, treatments with bacterial lysates can improve patient out-
comes and reduce costs.
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Objectives: To assess, from a societal perspective, the cost-effectiveness of 100% 
whey-based partially hydrolyzed infant formula (pHF-W) compared to standard 
cow’s milk formula (CMF) as an early, short-term nutritional intervention to pre-
vent atopic dermatitis (AD) in high-risk Singaporean infants. MethOds: A Markov 
model was developed to simulate, from birth through age 6, the incidence of AD 
and its ensuing burden in cohorts of high-risk infants fed with pHF-W or CMF 
during for the first 4 months of life. Epidemiologic and clinical data were from 
the German Infant Nutritional Intervention (GINI) trial. AD treatment patterns and 
outcomes were based on expert opinion. Key modeled outcomes included reduc-
tion in AD risk, time spent after an AD diagnosis, days with AD symptoms, quality-
adjusted life years (QALYs), and direct/indirect costs (in 2013 Singapore $). A 3% 
annual discount rate was used. Multivariate probabilistic sensitivity analysis was 
used to generate 95% probabilistic confidence intervals (CI) around the modeled 
outcomes. Results: Feeding high-risk infants pHF-W instead of CMF resulted in 
reductions of (i) 14-percentage points (95% CI: 3%, 24%) in the 6-year risk of AD, (ii) 
8.25 months (95% CI: 5.00, 11.61) in the time spent post-AD diagnosis, and (ii) 14.6 
days (95% CI: 8.9, 20.3) with AD symptoms; and in an increase of 0.022 QALYs (95% 
CI: 0.008, 0.074). Estimated AD-related discounted cost (all per child) when feeding 
high-risk infants with pHF-W vs. CMF were $1,316 (95% CI: $858, $2028) and $2,055 
(95% CI: $1,443, $2,820), respectively, for a net difference favoring pHF-W of $739 
(95% CI: $1,138, $326). The mean overall and annualized (undiscounted) cost of AD 
per child developing AD was $5,814 and $1,392, respectively. cOnclusiOns: This 
mathematical model suggests that the burden of AD in childhood is high and that 
feeding high-risk infants with pHF-W instead of CMF should reduce this burden.
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Objectives: To systematically review the economic evaluations of the Xiyanping 
injection to treat respiratory diseases. MethOds: Database as PubMed, ISI Web of 
knowledge, The Cochrane Library, CBM, WanFang Data, CNKI and VIP were electroni-
cally searched from inception to February 28st, 2014. Two reviewers independently 
screened studies according to inclusion and exclusion criteria and extracted data. 
Then, descriptive analysis was performed for included studies. A 10-item quality 
checklist modified was used to appraise the quality of studies. Results: 6 economic 
evaluations and cost studies were included of which 4 studies’ quality were low, 1 
was high and 1 was medium. All studies adequately documented effectiveness of 
interventions. However, the costs of interventions were not well reported in 2 studies. 
2 studies inadequately conducted sensitivity analysis and discounting. The disease of 
6 studies includingbronchitis(2studies), upper respiratory tract infection, herpangina, 
hand-foot-and-mouth disease and viral pneumonia. The studies result showed that 
cost-effectiveness of Xiyanping injection is poor than Tanreqing injection and have 
more adverse reaction in 2 studies and It is poor than Yanhuning injection, but less 
adverse reaction in 2 studies. Xiyanping injection is better than anti-viral medicine 
in 2 studies. 1study indicated that Xiyanping is more cost-effectiveness by atom-
ized than intravenous drip. cOnclusiOns: Xiyanping injection is not better than 
other proprietary Chinese medicine for the treatment of respiratory diseases in cost-
effectiveness analysis, however it is better than anti-viral medicine, and less adverse 
reaction. The quality of included studies is weaken the conclusion. There remains a 
strong need to improve the quality of reporting.
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reasons for self-medication, factors that influenced the choice of drug and source of 
drug. Results: People of all socio-demographic categories practice self-medication. 
A total of 76.8% of the respondents indulged in self-medication practices. Of which, 
33.0% used the medication inappropriately. The most frequently self-diagnosed ill-
nesses or symptoms of illnesses were: GI illnesses, cough/cold and headache/fever. 
Of these illnesses, more than 35% were less than 24 hours duration and nearly 80% 
less than seven days duration of illness. The reasons given by respondents for self-
diagnosis and self-medication were non-seriousness of the illnesses, for emergency 
use and prior experience about the illness with similar symptoms (39.7%) and even 
advice of non-physician health professional (33.5%). Whatever the duration of ill-
nesses and reasons for self-diagnosis, nearly 65% requested drugs by mentioning 
the names of the drugs and more than one-fifth by telling the symptoms of their 
illnesses. Requests for analgesics/antipyretics were very high (60%) followed by anti-
microbial drugs (40%) for all reported illness. Drug requested mostly in other con-
ditions include cold/cough suppressants, Gastro Intestinal drugs and very low for 
ORS. cOnclusiOns: The level of inappropriate drug use denotes self-medication 
as an unhealthy option, and it therefore, should be discouraged.
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Objectives: The study aimed to document the duration of tuberculosis (TB) treat-
ment, and its relationship with the characteristics of the patients. MethOds: This 
prospective follow-up cohort study was conducted at the chest clinic of Penang 
General Hospital between March 2010 and February 2011. Medical records and 
TB notification forms of all new smear positive pulmonary tuberculosis (PTB) 
patients, who were diagnosed during the study period, were reviewed to obtain 
socio-demographic and clinical data. Based on the standard guidelines, the normal 
benchmarks of treatment duration for the intensive- and continuation phase of 
TB treatment were taken as 2 and 4 months, respectively. A patient in whom the 
clinicians decided to extend the intensive phase (IP) for ≥ 2 weeks was categorized 
as a case of prolonged IP. The same criterion applied for the continuation phase 
(CP) of the treatment. Results: Out of the total 336 patients, 261 completed the 
IP of the treatment. Subsequently, 226 completed the CP. The average duration of 
TB treatment (n = 226) was 8.19 (SD 1.65) months. 49.4% (129 out of 261) patients 
completed the IP in 2 months, whereby only 37.6% patients (85 out of 226) com-
pleted the CP of the treatment in 4 months. In multiple logistic regression analysis, 
being a smoker, body mass index less than normal and a history of ≥ 4 weeks 
cough were the predictors of longer duration of the IP, while diabetes mellitus and 
presence of lung cavities were the only predictors of longer duration of the CP of 
the treatment. cOnclusiOns: The average duration of treatment in new smear 
positive PTB patients was longer than the targets set by World Health Organization. 
There is lacking a uniform international criterion to evaluate how well National 
Tuberculosis Program of Malaysia has performed in terms of managing duration 
of treatment in PTB patients.
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Objectives: The use of bacterial lysates as an immuno-modulator to boost immu-
nological response in patients with Recurrent Respiratory Tract Infections and its 
effects on the attack frequency of respiratory infection have been widely debated. 
We aimed to conduct our meta-analysis on the effect of bacterial lysates plus rou-
tine care versus routine care only on the attack frequency of respiratory infection 
in patients with Recurrent Respiratory Tract Infections. MethOds: We performed a 
systematic review of articles published from Jan 1, 2000 to Nov 10, 2013 by searching 
PubMed, Embase, Cochrane Central Register of Controlled Trials, and Wanfang and 
China National Knowledge Infrastructure. We included all randomised trials that 
compared outcomes between patients with Recurrent Respiratory Tract Infections 
receiving bacterial lysates plus routine care with those receiving routione care only. 
Eligible studies, determined by consensus with predefined criteria, were reviewed 
and data were extracted onto a standard form. We combined data to assess the 
primary outcome of attack frequency of respiratory infection using the DerSimonian 
and Laird random effects model. Results: Our search identified 128 reports, of 
which twelve studies met our inclusion criteria and were included in our meta-anal-
ysis. Analysis of the 12 randomised trials (959 patients) that reported an outcome 
on the attack frequency of respiratory infection showed that patients assigned to 
bacterial lysates plus routine care had a 2.942 reduction in respiratory tract infec-
tions compared to those assigned to routine care only (Weighted Mean Difference 
-2.942, 95% CI -3.600, -2.284). cOnclusiOns: Bacterial lysates are associated with a 
decreased risk of respiratory tract infections in patients with Recurrent Respiratory 
Tract Infections. Further studies are needed to identify the causes of respiratory 
tract infections and to assess whether the attack frequency of respiratory infection 
differs with varying treatments of bacterial lysates.
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wide [Stage I(n= 858): 0.906(0.006); Stage II(n= 1,091): 0.912(0.005); Stage III(n= 119): 
0.857(0.018); Stage IV(n= 13): 0.780(0.071)]. EQ-5D was not significantly different 
by 4-stage disease severity but showed a trend of deterioration in Stage III and 
IV. In the post-hoc analysis, COPD patients were divided into two-stage groups 
[group 1: Stage I and II; group 2: Stage III and IV]. In this analysis, 2-stage sever-
ity had a negative association with utility(p= 0.0009). cOnclusiOns: The results 
demonstrate that COPD impaires utility and shows a relationship between utility 
and COPD disease severity in Korea.
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Objectives: The burden of COPD is increasing in Korea.Health-realted quality 
of life among COPD patients should be considered. Few national strategies to 
prevent and manage COPD have been intervened. In this study, we investigate 
the factors associated with COPD patients’ quality of life. MethOds: Data of 
Korean National Health and Nutrition Examination Survey(KNHANES) 2007-2012 
were used. Multivariate regression anaysis was employed. Demographic variables 
(e.g. sex, age), socioeconomic status(SES) variables including education, insurance 
type, comorbidities(e.g. hypertension, diabetes, depressive disorder, cancer), sever-
ity of COPD, smoking were considered as independent variables. Results: We 
found that female(beta= -0.0387, p< 00001), age(beta= -0.0021,p< 0.0001), Medical 
aid bebeficieries(beta= -0.1001,p< 0.0001) showed a significantly lower score of 
EQ5D index. Mild(beta= 0.2001, p< 0.0001), moderate(beta= 0.1982, p< 0.0001), 
severe(beta= 0.1765, p< 0.0001) had significatly higher scores compared to that 
of very severe satge(GOLD IV). Education level also an important factor. Lower 
level of education(graduation from middle shcool or less) showed a negative 
association with EQ5D index score. Depression among comorbidities significantly 
worsened the quality of life of COPD paitents(beat= -0.7420, p< 0.0001). Smoking 
status(current smoker, ex-smoker, non-skmoker) did not show a significant dif-
ference. cOnclusiOns: Socio-economic status of COPD patients including sex, 
age, edication level and insurance type, were important factors related to the 
health-related quality of life. After controlling these factors, severe and depressive 
COPD patients reported their quality of life was significantly worsened. Strategies 
for COPD prevention and management should be developed and implemented. 
Improvement of health-related quality of life in COPD can be considered as an 
index of goals to achieve.
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Objectives: COPD is known as a disease with irreversible progress but 
preventable and managable. In Korea, COPD was ranked 12 with 242 DALYs 
(per 100,000) following diabetes(970 DALYs), cerebrovascular diseases(937DALYs) 
and asthma(709 DALYs). Health-related quality of life in COPD patients has not 
been investigated in Korea. MethOds: Data of Korean National Health and 
Nutrition Examination Survey(KNHANES) 2007-2012 were used. According to 
the GOLD criteria, we classified COPD patients into I-IV grades. EQ-5D index 
score were analysed by the severity of COPD and Comorbidities. Wilcoxon 
rank-sum test were used to compare quality of liife in COPD patients with 
that of the general population. SAS 9.3 version was used for analysis. Results: 
Utility score for the general population was 0.9291±0.1320 while COPD patients 
were scored 0.9042±0.1478 showing a significant difference(p< 0.0001). 
Comorbidities demosntrated a significant impact on the quality of life among 
COPD patients. Patients with hypertension(0.8863±0.1574), diabetes 
(0.882831±0.169179), cancer(0.8675±0.1691), and depression(0.8089±0.1784) showed 
a significantly lower utility score that those without comorbidities(p< 0.0001, 
p= 0.0042, p< 0.0001, p= 0.0687, respectively). According to the severity, 
mild(0.905754±0.140629) and moderate(0.9090±0.1465) COPD patients had a similar 
EQ5D index score. However, severe(0.8722±0.1724) and very severe(0.6816±0.2705) 
stages showed a significantly lower quality of life. We also found that diagnosed 
rate among COPD patients was only 2.96%. cOnclusiOns: As severity of COPD 
has shown a great impact on quality of life, preventable strategy and management 
should be developed. Especially early diagnosis and early detection will be the first 
step to take for COPD management in South Korea. To do so, interdisciplenary 
approach should be made.
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Objectives: To determine the pattern of self-medication among the people of 
region and to evaluate the factors associated with self-medication. MethOds: 
The data for this study was collected by the survey method in community phar-
macies. This was done by directly approaching the consumer for self-medication 
during the study period for their own use or as messengers for others. The struc-
tured research instrument was a simplified questionnaire, which sought informa-
tion on demographic background and self-medication practices. The elicited data 
include demography, use of drug without doctor’s prescription, type of drug used, 
